Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Characterization of multiple soluble immune checkpoints in individuals with different Mycobacterium tuberculosis infection status and dynamic changes during anti-tuberculosis treatment

Fig. 4

Dynamic changes of circulating sICs during anti-TB treatment. Patients with PTB and TBP were followed up during treatment. The levels of sICs in follow-up plasma were determined and compared with those in paired baseline plasma. The sBTLA level showed a significant decline in ATB patients after 6-month anti-TB treatment (P = 0.031). sPD-L1 showed an early decline in ATB patients (P = 0.002) within 6 months during anti-TB treatment. sPD-1 rose significantly during the 6-month treatment in ATB patients (P < 0.001) and the PTB subgroup (P < 0.001). sICs soluble immune checkpoints, TB tuberculosis, PTB pulmonary tuberculosis, TBP tuberculous pleurisy, ATB active tuberculosis

Back to article page